CA3010811A1 - Novel fusion protein comprising transcription modulation domain of p65 and protein transport domain and use thereof - Google Patents
Novel fusion protein comprising transcription modulation domain of p65 and protein transport domain and use thereof Download PDFInfo
- Publication number
- CA3010811A1 CA3010811A1 CA3010811A CA3010811A CA3010811A1 CA 3010811 A1 CA3010811 A1 CA 3010811A1 CA 3010811 A CA3010811 A CA 3010811A CA 3010811 A CA3010811 A CA 3010811A CA 3010811 A1 CA3010811 A1 CA 3010811A1
- Authority
- CA
- Canada
- Prior art keywords
- fusion protein
- kappa
- protein
- disease
- transcription
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 72
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 70
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 58
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 55
- 238000013518 transcription Methods 0.000 title claims abstract description 47
- 230000035897 transcription Effects 0.000 title claims abstract description 46
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 35
- 201000010099 disease Diseases 0.000 claims abstract description 32
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 230000000694 effects Effects 0.000 claims abstract description 20
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 13
- 230000006957 competitive inhibition Effects 0.000 claims abstract description 8
- 230000002265 prevention Effects 0.000 claims abstract description 7
- 230000026683 transduction Effects 0.000 claims description 31
- 238000010361 transduction Methods 0.000 claims description 31
- 206010037211 Psychomotor hyperactivity Diseases 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 206010040070 Septic Shock Diseases 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 8
- 230000036303 septic shock Effects 0.000 claims description 8
- 239000003112 inhibitor Substances 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 108010001859 Proto-Oncogene Proteins c-rel Proteins 0.000 claims description 5
- 102000000850 Proto-Oncogene Proteins c-rel Human genes 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 4
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 4
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000003120 Angiofibroma Diseases 0.000 claims description 2
- 108700031308 Antennapedia Homeodomain Proteins 0.000 claims description 2
- 101150019028 Antp gene Proteins 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 claims description 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 2
- 208000006029 Cardiomegaly Diseases 0.000 claims description 2
- 208000015943 Coeliac disease Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 206010010741 Conjunctivitis Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010011841 Dacryoadenitis acquired Diseases 0.000 claims description 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- 201000005569 Gout Diseases 0.000 claims description 2
- 208000003250 Mixed connective tissue disease Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 201000011152 Pemphigus Diseases 0.000 claims description 2
- 108010088535 Pep-1 peptide Proteins 0.000 claims description 2
- 101710176384 Peptide 1 Proteins 0.000 claims description 2
- 206010036030 Polyarthritis Diseases 0.000 claims description 2
- 101710149951 Protein Tat Proteins 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 208000019095 Radiation-induced disease Diseases 0.000 claims description 2
- 206010063837 Reperfusion injury Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 2
- 101710192266 Tegument protein VP22 Proteins 0.000 claims description 2
- 206010043781 Thyroiditis chronic Diseases 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 208000024780 Urticaria Diseases 0.000 claims description 2
- 201000009961 allergic asthma Diseases 0.000 claims description 2
- 230000000172 allergic effect Effects 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 201000004400 dacryoadenitis Diseases 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- 201000011066 hemangioma Diseases 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 2
- 208000030428 polyarticular arthritis Diseases 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 208000037803 restenosis Diseases 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 abstract description 16
- 102000004127 Cytokines Human genes 0.000 abstract description 15
- 102000000588 Interleukin-2 Human genes 0.000 abstract description 15
- 108010002350 Interleukin-2 Proteins 0.000 abstract description 15
- 230000002757 inflammatory effect Effects 0.000 abstract description 12
- 108091023040 Transcription factor Proteins 0.000 abstract description 10
- 230000028327 secretion Effects 0.000 abstract description 10
- 102000040945 Transcription factor Human genes 0.000 abstract description 9
- -1 IFN-? Proteins 0.000 abstract description 8
- 102000004388 Interleukin-4 Human genes 0.000 abstract description 8
- 108090000978 Interleukin-4 Proteins 0.000 abstract description 8
- 102000003814 Interleukin-10 Human genes 0.000 abstract description 7
- 108090000174 Interleukin-10 Proteins 0.000 abstract description 7
- 102000013691 Interleukin-17 Human genes 0.000 abstract description 7
- 108050003558 Interleukin-17 Proteins 0.000 abstract description 7
- 210000004988 splenocyte Anatomy 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 230000032258 transport Effects 0.000 abstract description 2
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 34
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 26
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 26
- 102100035100 Transcription factor p65 Human genes 0.000 description 19
- 239000002158 endotoxin Substances 0.000 description 16
- 230000014509 gene expression Effects 0.000 description 13
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 12
- 210000001744 T-lymphocyte Anatomy 0.000 description 10
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 238000010171 animal model Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 108060001084 Luciferase Proteins 0.000 description 6
- 239000005089 Luciferase Substances 0.000 description 6
- 108091006629 SLC13A2 Proteins 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 230000006044 T cell activation Effects 0.000 description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000002025 microglial effect Effects 0.000 description 5
- 235000019799 monosodium phosphate Nutrition 0.000 description 5
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 5
- 229910000162 sodium phosphate Inorganic materials 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 4
- 108010057466 NF-kappa B Proteins 0.000 description 4
- 102000003945 NF-kappa B Human genes 0.000 description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000004568 DNA-binding Effects 0.000 description 3
- 108010024212 E-Selectin Proteins 0.000 description 3
- 102100023471 E-selectin Human genes 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000002860 competitive effect Effects 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 108010013690 Methyl-Accepting Chemotaxis Proteins Proteins 0.000 description 2
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 2
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 238000010876 biochemical test Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 208000016097 disease of metabolism Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000012149 elution buffer Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000031146 intracellular signal transduction Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000010444 Acidosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 241000499489 Castor canadensis Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108010072135 Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100024649 Cell adhesion molecule 1 Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010021137 Hypovolaemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 description 1
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000011779 Menyanthes trifoliata Nutrition 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 102000007624 ZAP-70 Protein-Tyrosine Kinase Human genes 0.000 description 1
- 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 231100000668 minimum lethal dose Toxicity 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000030648 nucleus localization Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 101150069487 p65 gene Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- VSIVTUIKYVGDCX-UHFFFAOYSA-M sodium;4-[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].COC1=CC([N+]([O-])=O)=CC=C1[N+]1=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=NN1C1=CC=C([N+]([O-])=O)C=C1 VSIVTUIKYVGDCX-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention relates to a new fusion protein comprising a transcription modulation domain of p65 which is a subunit of the transcription factor NF-?B, and a protein transport domain and a use thereof. The fusion protein according to the present invention has the effects of inhibiting the transcription of NF-?B and IL-2 by competitive inhibition, inhibiting the secretion of inflammatory cytokines by LPS, and inhibiting the production of IL-2, IFN-?, IL-4, IL-17A and IL-10 in splenocytes, and thus can be useful as a composition for the prevention or treatment of NF-?B hyperactivity-related diseases.
Description
[DESCRIPTION]
[Invention Title]
NOVEL FUSION PROTEIN COMPRISING TRANSCRIPTION
MODULATION DOMAIN OF p65 AND PROTEIN TRANSPORT DOMAIN AND
USE THEREOF
[Technical Field]
The present invention was made with the support of Future Creation Science division of Korean Government under a subject No. NRF-2014R1A2A1A10052466, 2009-0083522(ERC), 10044494, and with the support of Yonsei University under a subject No. 2015-22-0065. The subject No. NRF-2014RI A2A1A10052466 was conducted under "Middle-Grade Researcher Supporting Project" within the project named "Development of new material for immunological disease customized for Treg, which is the control cell that invigorates the immune system" by "Industry-Academic Cooperation Foundation, YONSEI University" under the management of the National Research Foundation of Korea, from 1 November, 2014 to 31 October, 2017. The subject No. 2009-0083522(ERC) was conducted under "National Research Foundation of Korea- SRC(Science Research Center)/ERC(Engineering Research Center)"
within the project named "ERC/Center for Research on Fulfillment of Protein Function Control (3/3, level 2)" by "Industry-Academic Cooperation Foundation, YONSEI
University" under the management of the National Research Foundation of Korea, from 1 September, 2009 to 29 February, 2016. The subject No. 10044494 was conducted under "SW Computing Industry source technology development project"
within the project named "WiseKB: Development of Knowledge Base in Self-study Form Grounded on an Understanding of Bigdata and Deductive Technology" by "Saltlux Inc." under the management of the Institute for Information &
communications Technology Promotion, from 1 July, 2013 to 28 February, 2016.
The subject No. 2015-22-0065 was conducted under "Support for research within the university" within the project named "[Pioneers of the Future - International]
Development of Individually-customized New Medicine made out of Protein, for the Purpose of Controlling the Function of the Transcription Factor that has the Ability to Control Gene Expression of a Subset of T cell which is a Morfibic factor for Autoimmune Disease" by " Industry-Academic Cooperation Foundation, YONSEI
University" under the management of the Yonsei University, from 1 September to 31 August, 2016. The present invention relates to a novel fusion protein comprising the transcription modulation domain (TMD) of the transcription factor NF-KB subunit p65 and a protein transduction domain (PTD) and to the use thereof.
[Background Art]
Cytokines that are regulated by the transcription factor NF-KB include tumor necrosis factor-a (TNF-a), interleukin-1 (IL-1), interleukin-6 and granulocyte-macrophage colony stimulating factor (GM-CSF), and chemokines that are regulated by NF-KB include interleukin-8, macrophage-inflammatory protein-1 a (MIP-1a), methyl accepting chemotaxis protein-1 (MCP-1) and eotaxin. In addition, adhesion molecules that are regulated by NF-KB include E-selectin, vascular cell adhesion molecule-1 (VCAM-1), endothelial leukocyte adhesion molecule-1 (ELAM-1) and intercellular cell adhesion molecule-1 (ICAM-1), and inducible enzymes that are regulated by NF-KB
include cyclooxygenase-2 (COX-2) and the like. Thus, NF-KB is involved in almost all physiological reactions in the body.
The transcription factor NF-KB is composed of different subunits composed of homodimers or heterodimers. NF-KB proteins include RelA (p65), c-Rel, Rd-B, NF-KB1 (p50) and NF-KB2 (p52), and p50 and p52 are produced from NF-KB1 (p105) and
[Invention Title]
NOVEL FUSION PROTEIN COMPRISING TRANSCRIPTION
MODULATION DOMAIN OF p65 AND PROTEIN TRANSPORT DOMAIN AND
USE THEREOF
[Technical Field]
The present invention was made with the support of Future Creation Science division of Korean Government under a subject No. NRF-2014R1A2A1A10052466, 2009-0083522(ERC), 10044494, and with the support of Yonsei University under a subject No. 2015-22-0065. The subject No. NRF-2014RI A2A1A10052466 was conducted under "Middle-Grade Researcher Supporting Project" within the project named "Development of new material for immunological disease customized for Treg, which is the control cell that invigorates the immune system" by "Industry-Academic Cooperation Foundation, YONSEI University" under the management of the National Research Foundation of Korea, from 1 November, 2014 to 31 October, 2017. The subject No. 2009-0083522(ERC) was conducted under "National Research Foundation of Korea- SRC(Science Research Center)/ERC(Engineering Research Center)"
within the project named "ERC/Center for Research on Fulfillment of Protein Function Control (3/3, level 2)" by "Industry-Academic Cooperation Foundation, YONSEI
University" under the management of the National Research Foundation of Korea, from 1 September, 2009 to 29 February, 2016. The subject No. 10044494 was conducted under "SW Computing Industry source technology development project"
within the project named "WiseKB: Development of Knowledge Base in Self-study Form Grounded on an Understanding of Bigdata and Deductive Technology" by "Saltlux Inc." under the management of the Institute for Information &
communications Technology Promotion, from 1 July, 2013 to 28 February, 2016.
The subject No. 2015-22-0065 was conducted under "Support for research within the university" within the project named "[Pioneers of the Future - International]
Development of Individually-customized New Medicine made out of Protein, for the Purpose of Controlling the Function of the Transcription Factor that has the Ability to Control Gene Expression of a Subset of T cell which is a Morfibic factor for Autoimmune Disease" by " Industry-Academic Cooperation Foundation, YONSEI
University" under the management of the Yonsei University, from 1 September to 31 August, 2016. The present invention relates to a novel fusion protein comprising the transcription modulation domain (TMD) of the transcription factor NF-KB subunit p65 and a protein transduction domain (PTD) and to the use thereof.
[Background Art]
Cytokines that are regulated by the transcription factor NF-KB include tumor necrosis factor-a (TNF-a), interleukin-1 (IL-1), interleukin-6 and granulocyte-macrophage colony stimulating factor (GM-CSF), and chemokines that are regulated by NF-KB include interleukin-8, macrophage-inflammatory protein-1 a (MIP-1a), methyl accepting chemotaxis protein-1 (MCP-1) and eotaxin. In addition, adhesion molecules that are regulated by NF-KB include E-selectin, vascular cell adhesion molecule-1 (VCAM-1), endothelial leukocyte adhesion molecule-1 (ELAM-1) and intercellular cell adhesion molecule-1 (ICAM-1), and inducible enzymes that are regulated by NF-KB
include cyclooxygenase-2 (COX-2) and the like. Thus, NF-KB is involved in almost all physiological reactions in the body.
The transcription factor NF-KB is composed of different subunits composed of homodimers or heterodimers. NF-KB proteins include RelA (p65), c-Rel, Rd-B, NF-KB1 (p50) and NF-KB2 (p52), and p50 and p52 are produced from NF-KB1 (p105) and
2 NF-KB2 (p100), respectively, which are their precursors. The NF-KB proteins each contains about 300 amino acids, called the N-terminal Rel-homology domain (RHD), which is involved in dimerization, binding to specific DNA and reactions with hcB
protein. Furthermore, these proteins also contain a nuclear localization signal (N LS) that enables the proteins to act as transcription factors by localization to the nucleus. In addition, the NF-KB proteins may be classified, according to the presence or absence of the C-terminal transactivation domain (TAD), into class I (NF-KB1 and NF-x132) and class II (RelA/p65, RelB, and c-Rel). Class II has a transactivation domain that enables the NF-03 proteins to act as transcription factors without needing other NF-KB
domains, and class I has no transactivation domain. Dimers are formed between the NF-KB
proteins of the two classes to act as DNA transcription factors. Among the dimers, a p50/p65 dimer is most frequently present. RelA(p65), RelB and c-Rel have a C-terminal transactivation domain, and thus can activate the expression of their target genes.
On the contrary, p50 and p52, which are NF-x131 and NF-x132, respectively, have no C-terminal transactivation domain, and thus homodimers of p50 and p52 do not act as transcription factors if they do not have bound thereto proteins such as co-activators having a transactivation domain.
A protein transduction domain (PTD) is a short peptide having strong hydrophobicity, and is known to effectively transduce physiologically active molecules such as proteins, DNA and RNA, fused therewith, into cells. The present inventors have developed two PTDs to date, and the PTDs are disclosed in detail in WO
2003059940 and WO 2003059941. Because the protein transduction domain can transduce a physiologically active molecule not only into the cytoplasm but also into the nucleus, it has a property suitable for transducing a modified transcription factor, which is the key substance of the present invention, into the nucleus.
protein. Furthermore, these proteins also contain a nuclear localization signal (N LS) that enables the proteins to act as transcription factors by localization to the nucleus. In addition, the NF-KB proteins may be classified, according to the presence or absence of the C-terminal transactivation domain (TAD), into class I (NF-KB1 and NF-x132) and class II (RelA/p65, RelB, and c-Rel). Class II has a transactivation domain that enables the NF-03 proteins to act as transcription factors without needing other NF-KB
domains, and class I has no transactivation domain. Dimers are formed between the NF-KB
proteins of the two classes to act as DNA transcription factors. Among the dimers, a p50/p65 dimer is most frequently present. RelA(p65), RelB and c-Rel have a C-terminal transactivation domain, and thus can activate the expression of their target genes.
On the contrary, p50 and p52, which are NF-x131 and NF-x132, respectively, have no C-terminal transactivation domain, and thus homodimers of p50 and p52 do not act as transcription factors if they do not have bound thereto proteins such as co-activators having a transactivation domain.
A protein transduction domain (PTD) is a short peptide having strong hydrophobicity, and is known to effectively transduce physiologically active molecules such as proteins, DNA and RNA, fused therewith, into cells. The present inventors have developed two PTDs to date, and the PTDs are disclosed in detail in WO
2003059940 and WO 2003059941. Because the protein transduction domain can transduce a physiologically active molecule not only into the cytoplasm but also into the nucleus, it has a property suitable for transducing a modified transcription factor, which is the key substance of the present invention, into the nucleus.
3 Therefore, the present inventors have attempted to use a fusion protein comprising the transduction modulation domain of the NF-KB subunit p65 and a protein transduction domain to inhibit the transcription and activity of NF-KB by competitive inhibition to thereby treat effectively a disease caused by NF-KB
overactivity.
Throughout the specification, a number of publications and patent documents are referred to and cited. The disclosure of the cited publications and patent documents is incorporated herein by reference in its entirety to more clearly describe the state of the related art and the present invention.
[Disclosure]
[Technical Problem]
The present inventors have made extensive efforts to develop a substance capable of effectively preventing, alleviating or treating a disease caused by the overactivity of NF-KB. As a result, the present inventors have found that, when a fusion protein comprising the transcription modulation domain of the NF-KB subunit p65 and a protein transduction domain is used, it can inhibit the transcription and activity of NF-KB
by competitive inhibition, thereby completing the present invention.
Therefore, it is an object of the present invention to provide a fusion protein comprising the transcription modulation domain of the NF-KB subunit p65 and a protein transduction domain.
Another object of the present invention is to provide an inhibitor of NF-KB
transcription or activity, comprising the fusion protein of the present invention.
Still another object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of a disease related to NF-KB
overactivity, the pharmaceutical composition comprising the fusion protein of the present invention as an active ingredient.
overactivity.
Throughout the specification, a number of publications and patent documents are referred to and cited. The disclosure of the cited publications and patent documents is incorporated herein by reference in its entirety to more clearly describe the state of the related art and the present invention.
[Disclosure]
[Technical Problem]
The present inventors have made extensive efforts to develop a substance capable of effectively preventing, alleviating or treating a disease caused by the overactivity of NF-KB. As a result, the present inventors have found that, when a fusion protein comprising the transcription modulation domain of the NF-KB subunit p65 and a protein transduction domain is used, it can inhibit the transcription and activity of NF-KB
by competitive inhibition, thereby completing the present invention.
Therefore, it is an object of the present invention to provide a fusion protein comprising the transcription modulation domain of the NF-KB subunit p65 and a protein transduction domain.
Another object of the present invention is to provide an inhibitor of NF-KB
transcription or activity, comprising the fusion protein of the present invention.
Still another object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of a disease related to NF-KB
overactivity, the pharmaceutical composition comprising the fusion protein of the present invention as an active ingredient.
4 Still another object of the present invention is to provide a method for inhibiting transcription or activity of NF-KB, and a method of preventing, improving or treating a disease related to NF-KB overactivity.
Other objects and advantages of the present invention will become more apparent from the following detailed description, the appended claims and the accompanying drawings.
[Technical Solution]
In accordance with one aspect of the present invention, there is provided a fusion protein comprising the transcription modulation domain of the NF-KB subunit p65 and a protein transduction domain. The fusion protein of the present invention inhibits NF-KB
transcription by competitive inhibition.
The present inventors have made extensive efforts to develop a substance capable of effectively preventing, alleviating or treating a disease caused by NF-KB
overactivity. As a result, the present inventors have found that, when a fusion protein comprising the transcription modulation domain of the NF-KB subunit p65 and a protein transduction domain is used, it can inhibit the transcription and activity of NF-KB by competitive inhibition.
As used herein, the term "transcription modulation domain" means a portion of a transcription factor, which is composed only of a DNA binding domain without a transactivation domain. As demonstrated in the examples below, the fusion protein of the present invention has no transactivation domain, but has a DNA binding domain, and thus it can bind to a target promoter, but cannot promote transcription.
Accordingly, the fusion protein of the present invention is a dominant negative mutant for the NF-KB gene, and thus can act as a competitive inhibitor against wild-type NF-KB in cells to inhibit the
Other objects and advantages of the present invention will become more apparent from the following detailed description, the appended claims and the accompanying drawings.
[Technical Solution]
In accordance with one aspect of the present invention, there is provided a fusion protein comprising the transcription modulation domain of the NF-KB subunit p65 and a protein transduction domain. The fusion protein of the present invention inhibits NF-KB
transcription by competitive inhibition.
The present inventors have made extensive efforts to develop a substance capable of effectively preventing, alleviating or treating a disease caused by NF-KB
overactivity. As a result, the present inventors have found that, when a fusion protein comprising the transcription modulation domain of the NF-KB subunit p65 and a protein transduction domain is used, it can inhibit the transcription and activity of NF-KB by competitive inhibition.
As used herein, the term "transcription modulation domain" means a portion of a transcription factor, which is composed only of a DNA binding domain without a transactivation domain. As demonstrated in the examples below, the fusion protein of the present invention has no transactivation domain, but has a DNA binding domain, and thus it can bind to a target promoter, but cannot promote transcription.
Accordingly, the fusion protein of the present invention is a dominant negative mutant for the NF-KB gene, and thus can act as a competitive inhibitor against wild-type NF-KB in cells to inhibit the
5 transcription and activity of NF-KB.
In one embodiment, NF-KB that is used in the present invention is NF-KB
selected from the group consisting of RelA (p65), c-Rel, Rel-B, NF-KI31 (p50) and NF-032 (p52). In a specific embodiment, NF-KB that is used in the present invention is RelA (p65).
In one embodiment, the transcription modulation domain of NF-KB that is used in the present invention comprises an amino acid sequence of SEQ ID NO: I. In another embodiment of the present invention, the transcription modulation domain of NF-KB, which comprises the amino acid sequence of SEQ ID NO: 1, is encoded by a nucleotide sequence of SEQ ID NO: 3.
As used herein, the term "protein transduction domain" is a short, strongly hydrophobic peptide consisting of 7-50 amino acids, and means a domain capable of transducing not only a protein having a molecular weight of 120 kDa or more, but also DNA or RNA, into cells. As demonstrated in the examples below, it could be seen that, unlike the fusion protein of the present invention, a protein to which the protein transduction domain of the present invention is not attached (that is, p65-TMD
composed only of the transcription modulation domain) has no effects on the inhibition of transcription of NF-03 and IL-2, the inhibition of LPS-induced secretion of inflammatory cytokines, and the inhibition of production of IL-2, IFN-y, IL-4, and IL-10 in splenocytes.
According to one embodiment of the present invention, the protein transduction domain that is used in the present invention is selected from the group consisting of Hph-1, Sim-2, Tat, VP22, Antp (antennapedia), Pep-1 (peptide-1), PTD-5 (protein transduction domain-5), 7R, 9R, 11R and CTP (cytoplamic transduction peptide).
As used herein, the terms "7R", "9R" and "11" mean peptides consisting of 7, 9 and 11
In one embodiment, NF-KB that is used in the present invention is NF-KB
selected from the group consisting of RelA (p65), c-Rel, Rel-B, NF-KI31 (p50) and NF-032 (p52). In a specific embodiment, NF-KB that is used in the present invention is RelA (p65).
In one embodiment, the transcription modulation domain of NF-KB that is used in the present invention comprises an amino acid sequence of SEQ ID NO: I. In another embodiment of the present invention, the transcription modulation domain of NF-KB, which comprises the amino acid sequence of SEQ ID NO: 1, is encoded by a nucleotide sequence of SEQ ID NO: 3.
As used herein, the term "protein transduction domain" is a short, strongly hydrophobic peptide consisting of 7-50 amino acids, and means a domain capable of transducing not only a protein having a molecular weight of 120 kDa or more, but also DNA or RNA, into cells. As demonstrated in the examples below, it could be seen that, unlike the fusion protein of the present invention, a protein to which the protein transduction domain of the present invention is not attached (that is, p65-TMD
composed only of the transcription modulation domain) has no effects on the inhibition of transcription of NF-03 and IL-2, the inhibition of LPS-induced secretion of inflammatory cytokines, and the inhibition of production of IL-2, IFN-y, IL-4, and IL-10 in splenocytes.
According to one embodiment of the present invention, the protein transduction domain that is used in the present invention is selected from the group consisting of Hph-1, Sim-2, Tat, VP22, Antp (antennapedia), Pep-1 (peptide-1), PTD-5 (protein transduction domain-5), 7R, 9R, 11R and CTP (cytoplamic transduction peptide).
As used herein, the terms "7R", "9R" and "11" mean peptides consisting of 7, 9 and 11
6 arginine residues, respectively. According to a specific embodiment, the protein transduction domain that is used in the present invention is Hph-1.
According to one embodiment of the present invention, the protein transduction domain that is used in the present invention comprises an amino acid sequence of SEQ
ID NO: 2. According to another embodiment of the present invention, the protein transduction domain comprising the amino acid sequence of SEQ ID NO: 2 according to the present invention is encoded by a nucleotide sequence of SEQ ID NO: 4.
According to one embodiment of the present invention, the fusion protein of the present invention comprises an amino acid sequence of SEQ ID NO: 5. According to a specific embodiment of the present invention, a fusion protein comprising an amino acid sequence of SEQ ID NO: 5 is encoded by a nucleotide sequence of SEQ ID NO: 6.
In accordance with another aspect of the present invention, there is provided an inhibitor of NF-KB transcription or activity, comprising the fusion protein of the present invention. As demonstrated in the examples below, it was shown that the fusion protein of the present invention could inhibit the transcription and activity of NE-KB
and IL-2 (FIG. 6), inhibit the LPS-induced secretion of inflammatory cytokines (FIG.
According to one embodiment of the present invention, the protein transduction domain that is used in the present invention comprises an amino acid sequence of SEQ
ID NO: 2. According to another embodiment of the present invention, the protein transduction domain comprising the amino acid sequence of SEQ ID NO: 2 according to the present invention is encoded by a nucleotide sequence of SEQ ID NO: 4.
According to one embodiment of the present invention, the fusion protein of the present invention comprises an amino acid sequence of SEQ ID NO: 5. According to a specific embodiment of the present invention, a fusion protein comprising an amino acid sequence of SEQ ID NO: 5 is encoded by a nucleotide sequence of SEQ ID NO: 6.
In accordance with another aspect of the present invention, there is provided an inhibitor of NF-KB transcription or activity, comprising the fusion protein of the present invention. As demonstrated in the examples below, it was shown that the fusion protein of the present invention could inhibit the transcription and activity of NE-KB
and IL-2 (FIG. 6), inhibit the LPS-induced secretion of inflammatory cytokines (FIG.
7), and inhibit the production of IL-2, IFN-y, IL-4, IL-17A and IL-10 which are expressed by T-een activation stimulated by anti-CD3/CD28 in splenocytes (FIG. 9), indicating that the fusion protein can inhibit the NE-KB-induced proliferation and differentiation of T cells and the NE-KB-induced secretion of inflammatory cytokines. This suggests that the fusion protein of the present invention can effectively prevent, alleviate or treat a disease caused by the overactivity of NF-KB.
In accordance with another aspect of the present invention, there is provided a pharmaceutical composition for the prevention or treatment of a disease related to NF-KB
overactivity, the pharmaceutical composition comprising the fusion protein of the present invention as an active ingredient.
As used herein, the term "treatment" refers to: (a) suppressing the progression of disease, disorder, or symptom; (b) reducing disease, disorder, or symptom; or (c) curing the disease, disorder, or symptom. The composition of the present invention suppresses the development of symptoms of metabolic disease, or removes or reduces the symptoms of metabolic disease. Therefore, the composition of the present invention may be a composition for treating disease related to NF-KB overactivity, or may be applied as a treatment adjuvant for the disease when administered with other composition for treating a disease related to NF-03 overactivity. As used herein, the term "treatment"
or "treatment agent" includes a meaning of "treatment aid" or "therapeutic adjuvant".
As demonstrated in the examples below, the fusion protein of the present invention inhibits the transcription of NF-KB and IL-2, inhibits the LPS-induced secretion of inflammatory cytokines, and inhibits the production of IL-2, IFN-y, IL-4, IL-17A and IL-10 in splenocytes. Thus, the fusion protein of the present invention may be effectively used as a composition for efficiently preventing or treating various diseases related to NF-K13 overactivity.
In one embodiment of the present invention, the disease related to NF-KB
overactivity in the present invention is an inflammatory disease or an autoimmune disease. In another embodiment of the present invention, the disease related to NF-KI3 overactivity in the present invention is a disease selected from the group consisting of septic shock, allergic asthma, allergic nasitis, atopic dermatitis, systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, dacryoadenitis, Alzheimer's disease, stroke, arteriosclerosis, vascular restenosis, type I diabetes, type II diabetes, urticaria, conjunctivitis, psoriasis, systemic inflammatory response syndrome, polymyositis, dermatomyositis, polyarthritis nodosa, mixed connective tissue disease,
In accordance with another aspect of the present invention, there is provided a pharmaceutical composition for the prevention or treatment of a disease related to NF-KB
overactivity, the pharmaceutical composition comprising the fusion protein of the present invention as an active ingredient.
As used herein, the term "treatment" refers to: (a) suppressing the progression of disease, disorder, or symptom; (b) reducing disease, disorder, or symptom; or (c) curing the disease, disorder, or symptom. The composition of the present invention suppresses the development of symptoms of metabolic disease, or removes or reduces the symptoms of metabolic disease. Therefore, the composition of the present invention may be a composition for treating disease related to NF-KB overactivity, or may be applied as a treatment adjuvant for the disease when administered with other composition for treating a disease related to NF-03 overactivity. As used herein, the term "treatment"
or "treatment agent" includes a meaning of "treatment aid" or "therapeutic adjuvant".
As demonstrated in the examples below, the fusion protein of the present invention inhibits the transcription of NF-KB and IL-2, inhibits the LPS-induced secretion of inflammatory cytokines, and inhibits the production of IL-2, IFN-y, IL-4, IL-17A and IL-10 in splenocytes. Thus, the fusion protein of the present invention may be effectively used as a composition for efficiently preventing or treating various diseases related to NF-K13 overactivity.
In one embodiment of the present invention, the disease related to NF-KB
overactivity in the present invention is an inflammatory disease or an autoimmune disease. In another embodiment of the present invention, the disease related to NF-KI3 overactivity in the present invention is a disease selected from the group consisting of septic shock, allergic asthma, allergic nasitis, atopic dermatitis, systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, dacryoadenitis, Alzheimer's disease, stroke, arteriosclerosis, vascular restenosis, type I diabetes, type II diabetes, urticaria, conjunctivitis, psoriasis, systemic inflammatory response syndrome, polymyositis, dermatomyositis, polyarthritis nodosa, mixed connective tissue disease,
8 Sjogren's syndrome, gout, Parkinson's disease, amyotrophic lateral sclerosis, diabetic retinopathy, multiple sclerosis, Crohn's disease, chronic thyroiditis, Celiac disease, myasthenia gravis, pemphigus vulgaris, viral diseases, bacterial diseases, radiation-induced disorders, arteriosclerosis, hemangioma, angiofibroma, reperfusion injury, and cardiac hypertrophy. According to a specific embodiment, the disease related to NF-KB
overactivity in the present invention is septic shock. Septic shock that causes a severe systemic inflammatory reaction due to microbial infection shows abnormalities in the cardiovascular system and vasomotor factors by endotoxins and inflammatory mediators circulating the blood vessels. For this reason, hypovolemia occurs due to dehydration and leakage of intravascular liquid, and vascular contraction and relaxation in capillary vessels occur to cause abnormalities in blood supply, and vasculitis and thrombosis make tissue reflux more difficult, resulting in tissue hypoxia and metabolic acidosis. In particular, endotoxins activate NF-KB in immunocytes (macrophages, granulocytes, dendritic cells, and lymphocytes) to secrete cytokines such as tumor necrosis factor, linterleukin-1 and linterleukin-6, and such cytokines stimulate neutrophils, endothelial cells, platelets or inflammatory mediator-releasing cells to cause systemic reactions. As demonstrated in the examples below, it was shown that the fusion protein of the present invention inhibited the secretion of inflammatory cytokines in septic shock models induced by LPS and increased the survival rate of the models (FIG. 10).
Thus, it can be seen that the fusion protein of the present invention is effective for the prevention or treatment of a disease related to NF-KB overactivity.
If the composition of the present invention is prepared as a pharmaceutical composition, the pharmaceutical composition of the present invention contains a pharmaceutically acceptable carrier. Examples of the pharmaceutically acceptable carrier that is contained in the pharmaceutical composition of the present invention
overactivity in the present invention is septic shock. Septic shock that causes a severe systemic inflammatory reaction due to microbial infection shows abnormalities in the cardiovascular system and vasomotor factors by endotoxins and inflammatory mediators circulating the blood vessels. For this reason, hypovolemia occurs due to dehydration and leakage of intravascular liquid, and vascular contraction and relaxation in capillary vessels occur to cause abnormalities in blood supply, and vasculitis and thrombosis make tissue reflux more difficult, resulting in tissue hypoxia and metabolic acidosis. In particular, endotoxins activate NF-KB in immunocytes (macrophages, granulocytes, dendritic cells, and lymphocytes) to secrete cytokines such as tumor necrosis factor, linterleukin-1 and linterleukin-6, and such cytokines stimulate neutrophils, endothelial cells, platelets or inflammatory mediator-releasing cells to cause systemic reactions. As demonstrated in the examples below, it was shown that the fusion protein of the present invention inhibited the secretion of inflammatory cytokines in septic shock models induced by LPS and increased the survival rate of the models (FIG. 10).
Thus, it can be seen that the fusion protein of the present invention is effective for the prevention or treatment of a disease related to NF-KB overactivity.
If the composition of the present invention is prepared as a pharmaceutical composition, the pharmaceutical composition of the present invention contains a pharmaceutically acceptable carrier. Examples of the pharmaceutically acceptable carrier that is contained in the pharmaceutical composition of the present invention
9 include, but are not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinyl pyrrolidone, cellulose, water, syrup, methyl cellulose, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil, which are commonly used in formulations. The pharmaceutical composition may further contain, in addition to the above-described components, a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative or the like. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington's Pharmaceutical Sciences (191" ed., 1995).
The pharmaceutical composition of the present invention may be administered orally or parenterally.
When the pharmaceutical composition is administered parenterally, it may be injected intravenously, subcutaneously, intramuscularly, intraperitoneally, transdermally, or the like. In one embodiment of the present invention, the pharmaceutical composition of the present invention may be administered by intraperitoneal injection.
The suitable dose of the pharmaceutical composition of the present invention may vary depending on various factors, including the formulation method, the mode of administration, the patient's age, weight, sex, disease condition and diet, the time of administration, the route of administration, the rate of excretion, and reaction sensitivity.
The daily dose of the pharmaceutical composition according to the present invention is, for example, 0.0001-1000 mg/kg.
The pharmaceutical composition of the present invention may be formulated with a pharmaceutically acceptable carrier and/or excipient in a unit dosage form or a multiple dosage form, according to a method that can be easily carried out by a skilled person in the art to which the present invention pertains. Herein, the formulation may be a solution in oil or an aqueous medium, a suspension, syrup, an emulsifying solution, an extract, powder, granules, a tablet, or a capsule, and may further contain a dispersing agent or a stabilizing agent.
Because the NF-KB transcription or activity inhibitor of the present invention and the composition for the prevention or treatment of a disease related to NF-KB
overactivity according to the present invention commonly comprise the above-described fusion protein, the description of the contents that are common in relation to the fusion protein is omitted in order to avoid excessive complexity of description.
In accordance with another aspect of the present invention, there is provided a method of inhibiting transcription or activity of NF- K B, the method comprising administering a composition comprising the fusion protein of the present invention as an active ingredient.
In accordance with another aspect of the present invention, there is provided a method of preventing, improving or treating a disease related to NF-KB
overactivity, the method comprising administering, to a subject in need, a composition comprising the fusion protein of the present invention as an active ingredient.
As used herein, the term "administration" or "administer" refers to a method wherein a therapeutically effective amount of the composition of the present invention is directly administered to a subject to form the same amount thereof in the body of the subject. Therefore, the term "administer" includes the injection of an active ingredient (the fusion protein of the present invention) around a site of lesion, and thus the term "administer" is used in the same meaning as the term "inject".
The term "therapeutically effective amount" of the composition refers to the content, which is sufficient to provide a therapeutic or prophylactic effect to a subject to be administered, and thus the term has a meaning including "prophylactically effective amount". As used herein, the term "subject" includes, but is not limited to, human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, monkey, chimpanzee, beaver, or rhesus monkey. Specifically, the subject of the present invention is human.
Since the method of inhibiting the transcription or activity NF-KB, and the method for preventing, improving or treating the disease related to NF-KB
overactivity commonly comprise the above-described fusion protein and the use thereof, descriptions of overlapping contents therebetween are omitted to avoid excessive complication of the specification due to repeated descriptions thereof.
[Advantageous Effects]
The features and advantages of the present invention are as follows.
(a) The present invention provides a fusion protein comprising the transcription modulation domain of the NF-KB subunit p65 and a protein transduction domain, and the use thereof.
(b) The fusion protein of the present invention has the effects of inhibiting the transcription of NF-KB and IL-2 by competitive inhibition and inhibiting the LPS-induced secretion of inflammatory cytokines and also inhibiting the production of IL-2, IFN-y, IL-4, IL-17A and IL-10 in splenocytes, and thus can be effectively used as a composition for the prevention or treatment of a disease related to NF-KB
overactivity.
[Description of Drawings]
FIG. 1 shows the structure of a fusion protein (nt-p65-TMD) of a p65-transcription modulation domain (p65-TMD) and Mph-1 (PTD) according to an embodiment of the present invention. DBD: DNA binding domain; IBD: IKB binding domain; NLS: nuclear localization sequence; TAD: transactivation domain.
FIG. 2 shows the results of Coomassie blue staining of the fusion protein (nt-p65-TMD) according to the present invention.
FIG. 3 shows the results of transduction of the fusion protein (nt-p65-TMD) of the present invention into BV2 and Jurkat T cells.
FIG. 4 shows the results of transduction of the fusion protein (nt-p65-TMD) of the present invention into the nuclei of BV2 and HeLa cells.
FIG. 5 shows the results of cytotoxicity of the fusion protein (nt-p65-TMD) of the present invention in BV2 and spleen cells.
FIG. 6 shows the effect of the fusion protein (nt-p65-TMD) of the present invention on competitive inhibition of transcription.
FIG. 7 shows the effect of the fusion protein (nt-p65-TMD) of the present invention on the inhibition of LPS-induced expression of TNF-a, IL-113 and IL-6.
FIG. 8a shows results indicating that the fusion protein (nt-p65-TMD) of the present invention specifically inhibits NF-KB transcription induced by T-cell activation stimulated by anti-CD3/CD28. FIG. 8b show results indicating that fusion protein (nt-p65-TMD) of the present invention does not influence signal transduction pathways induced by T-cell activation stimulated by anti-CD3/CD28.
FIG. 9 shows results indicating that the fusion protein (nt-p65-TMD) of the present invention inhibits the expression of IL-2, IFN-y, IL-4, IL-17A and IL-
The pharmaceutical composition of the present invention may be administered orally or parenterally.
When the pharmaceutical composition is administered parenterally, it may be injected intravenously, subcutaneously, intramuscularly, intraperitoneally, transdermally, or the like. In one embodiment of the present invention, the pharmaceutical composition of the present invention may be administered by intraperitoneal injection.
The suitable dose of the pharmaceutical composition of the present invention may vary depending on various factors, including the formulation method, the mode of administration, the patient's age, weight, sex, disease condition and diet, the time of administration, the route of administration, the rate of excretion, and reaction sensitivity.
The daily dose of the pharmaceutical composition according to the present invention is, for example, 0.0001-1000 mg/kg.
The pharmaceutical composition of the present invention may be formulated with a pharmaceutically acceptable carrier and/or excipient in a unit dosage form or a multiple dosage form, according to a method that can be easily carried out by a skilled person in the art to which the present invention pertains. Herein, the formulation may be a solution in oil or an aqueous medium, a suspension, syrup, an emulsifying solution, an extract, powder, granules, a tablet, or a capsule, and may further contain a dispersing agent or a stabilizing agent.
Because the NF-KB transcription or activity inhibitor of the present invention and the composition for the prevention or treatment of a disease related to NF-KB
overactivity according to the present invention commonly comprise the above-described fusion protein, the description of the contents that are common in relation to the fusion protein is omitted in order to avoid excessive complexity of description.
In accordance with another aspect of the present invention, there is provided a method of inhibiting transcription or activity of NF- K B, the method comprising administering a composition comprising the fusion protein of the present invention as an active ingredient.
In accordance with another aspect of the present invention, there is provided a method of preventing, improving or treating a disease related to NF-KB
overactivity, the method comprising administering, to a subject in need, a composition comprising the fusion protein of the present invention as an active ingredient.
As used herein, the term "administration" or "administer" refers to a method wherein a therapeutically effective amount of the composition of the present invention is directly administered to a subject to form the same amount thereof in the body of the subject. Therefore, the term "administer" includes the injection of an active ingredient (the fusion protein of the present invention) around a site of lesion, and thus the term "administer" is used in the same meaning as the term "inject".
The term "therapeutically effective amount" of the composition refers to the content, which is sufficient to provide a therapeutic or prophylactic effect to a subject to be administered, and thus the term has a meaning including "prophylactically effective amount". As used herein, the term "subject" includes, but is not limited to, human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, monkey, chimpanzee, beaver, or rhesus monkey. Specifically, the subject of the present invention is human.
Since the method of inhibiting the transcription or activity NF-KB, and the method for preventing, improving or treating the disease related to NF-KB
overactivity commonly comprise the above-described fusion protein and the use thereof, descriptions of overlapping contents therebetween are omitted to avoid excessive complication of the specification due to repeated descriptions thereof.
[Advantageous Effects]
The features and advantages of the present invention are as follows.
(a) The present invention provides a fusion protein comprising the transcription modulation domain of the NF-KB subunit p65 and a protein transduction domain, and the use thereof.
(b) The fusion protein of the present invention has the effects of inhibiting the transcription of NF-KB and IL-2 by competitive inhibition and inhibiting the LPS-induced secretion of inflammatory cytokines and also inhibiting the production of IL-2, IFN-y, IL-4, IL-17A and IL-10 in splenocytes, and thus can be effectively used as a composition for the prevention or treatment of a disease related to NF-KB
overactivity.
[Description of Drawings]
FIG. 1 shows the structure of a fusion protein (nt-p65-TMD) of a p65-transcription modulation domain (p65-TMD) and Mph-1 (PTD) according to an embodiment of the present invention. DBD: DNA binding domain; IBD: IKB binding domain; NLS: nuclear localization sequence; TAD: transactivation domain.
FIG. 2 shows the results of Coomassie blue staining of the fusion protein (nt-p65-TMD) according to the present invention.
FIG. 3 shows the results of transduction of the fusion protein (nt-p65-TMD) of the present invention into BV2 and Jurkat T cells.
FIG. 4 shows the results of transduction of the fusion protein (nt-p65-TMD) of the present invention into the nuclei of BV2 and HeLa cells.
FIG. 5 shows the results of cytotoxicity of the fusion protein (nt-p65-TMD) of the present invention in BV2 and spleen cells.
FIG. 6 shows the effect of the fusion protein (nt-p65-TMD) of the present invention on competitive inhibition of transcription.
FIG. 7 shows the effect of the fusion protein (nt-p65-TMD) of the present invention on the inhibition of LPS-induced expression of TNF-a, IL-113 and IL-6.
FIG. 8a shows results indicating that the fusion protein (nt-p65-TMD) of the present invention specifically inhibits NF-KB transcription induced by T-cell activation stimulated by anti-CD3/CD28. FIG. 8b show results indicating that fusion protein (nt-p65-TMD) of the present invention does not influence signal transduction pathways induced by T-cell activation stimulated by anti-CD3/CD28.
FIG. 9 shows results indicating that the fusion protein (nt-p65-TMD) of the present invention inhibits the expression of IL-2, IFN-y, IL-4, IL-17A and IL-
10, induced by T-cell activation stimulated by anti-CD3/CD28.
FIG. 10 shows results indicating that the fusion protein (nt-p65-TMD) of the present invention inhibits the secretion of inflammatory cytokines (TNF-a, IL-113 and IL-6) in septic shock animal models to thereby increase the survival rate of the animal models.
(Best Mode]
Hereinafter, the present invention will be described in further detail with reference to examples. It will be obvious to those skilled in the art that these examples are for illustrative purposes and are not intended to limit the scope of the present invention.
Examples Example 1: Preparation of a Recombinant Fusion Protein Comprising p65 Transcription Modulation Domain and Protein Transduction Domain The protein transduction domain (PTD) Hph-1 (SEQ ID NO: 4) was cloned into the p65 transcription modulation domain p65-TMD (SEQ ID NO: 2) and a pET-28a(+) vector (Novagen) to thereby construct a recombinant fusion DNA (nt-p65-TMD) (SEQ
ID NO: 6). The recombinant fusion DNA was transformed into a BL21 CodonPlus(DE3)-RIPL E. coli strain (Invitrogen). The transformed strain was cultured, and then treated with 1 mM IPTG (isopropy143-D-thiogalactopyranoside, Duchefa), after which protein expression in the strain was induced at 37 C for 5 hours. Next, only the cells were harvested, lysed with lysis buffer (10 mM imidazole, 50 mM NaH2PO4, mM NaC1, pH 8.0), and then disrupted with a homogenizer. The fusion protein was bound to Ni-NTA beads (Qiagen) by 6 histidine residues linked to the upstream region of the protein. The protein was loaded onto HisTrap chromatography columns (Bio-Rad), and washed sufficiently with washing buffer (30 mM imidazole, 50 mM NaH2PO4, mM NaC1, pH 8.0), and the protein was eluted with elution buffer (250 mM
imidazole, 50 mM NaH2PO4, 300 mM NaC1 and pH 8.0). Using PD-10 Sephadex G-25 (GE
Healthcare), imidazole and NaC1 were removed while the buffer was replaced with 10%
glycerol-containing PBS. Because the obtained protein contained endotoxins such as LPS, it was purified once more using SP beads (SP Sepharose 1m Fast Flow, GE
Healthcare) to remove the endotoxins. The resulting protein was bound using binding buffer (50 mM NaH2PO4, 300 mM NaC1, pH 6.0), and then loaded onto a column and eluted with elution buffer (50 mM NaH2PO4, 2 M NaC1, pH 6.0). Finally, NaCI
was removed using PD-10 Sephadex G-25, and the buffer was placed with 10% glycerol-containing PBS, after which the resulting protein (SEQ ID NO: 5, recombinant fusion protein) was stored at 80 C until use in experiments (see FIGS. 1 and 2).
Example 2: Analysis of Intracellular Transduction of nt-p65-TMD
Recombinant Fusion Protein 2-1: Analysis of Intracellular Transduction by Western Blotting BV2 microglial cells and Jurkat T cells were incubated with the recombinant fusion protein (nt-p65-TMD) at varying protein concentrations (0, 0.1, 0.5, 1, 2 and 5 [tM) or for varying times (0, 1, 2, 4, 6, 12, 24 and 48 hours), and whether or not the fusion protein was transduced was analyzed by Western blotting.
As a result, it was shown that the fusion protein was well transduced in proportion to the concentration thereof and was continuously transduced even at 48 hours while the protein in the cell culture maintained its structure (see FIG. 3).
2-2: Analysis of Whether or Not Fusion Protein is Transduced to Nucleus of Cells, by Use of Antibody 5 ptM of the recombinant fusion protein (nt-p65-TMD) of Example 1 was incubated with BV2 microglial cells and HeLa cells for 1 hour and washed with PBS, after which the cells were treated with 0.2% Triton X-100 (Sigma-Aldrich) to form an opening, and a fluorescence-labeled antibody was bound to the recombinant fusion protein through the opening. Next, the nucleus of the cells was stained with DAPI dye (Invitrogen), and then the location of fluorescence was determined by a fluorescence microscope to thereby determine the location to which the recombinant fusion protein was transduced.
As a result, it was shown that the fusion protein was well transduced to the nucleus of the cells by the property of the PTD (see FIG. 4).
Example 3: Analysis of Cytotoxicity of nt-p65-TMD Recombinant Fusion Protein In order to confirm that the protein obtained from the E. coli strain by expression is completely free of LPS so that it is not toxic to cells or animals, a cytotoxicity test was performed. Varying concentrations of the protein were transduced into BV2 microglial cells and splenocytes, and then the cells were incubated with WST-8, a substrate that develops color by dehydrogenase present in living cells.
As a result, it could be seen that the cells treated with the fusion protein showed no cytotoxicity regardless of the concentration of the fusion protein, unlike cells not treated with the protein (FIG. 5).
Example 4: Confirmation of the Effect of nt-p65-TMD Recombinant Fusion Protein on Specific Inhibition of Transcription Factor 4-1: Confirmation of Inhibitory Effect against Transcription of NF-KB and IL-2 in HEI(293T Cells To directly confirm whether or not the nt-p65-TMD recombinant fusion protein of Example 1 binds to the promoters of the NF-03 and 1L-2 cytokine genes in place of wild-type p65 to inhibit the expression of the genes, luciferase reporter gene was used.
First, each of NF-KB and IL-2 promoters and wild-type p65 gene, which have luciferase in the downstream region, was transfected into the nucleus of HEK293T cells, and then the cells were treated with the nt-p65-TMD recombinant fusion protein.
As a result, it could be seen that, when the cells were treated with the recombinant fusion protein, the expression of luciferase in the cells was effectively inhibited. This suggests that nt-p65-TMD acted as a competitive inhibitor of wild-type p65 to block the p65-binding site of each of the NF-KB and IL-2 promoters (see FIG. 6).
4-2: Confirmation of Inhibitory Effect against Secretion of Inflammatory Cytokines in BV2 Microglial Cells BV2 microglial cells were treated with the nt-p65-TMD recombinant fusion protein of Example 1, and after 1 hour, the cells were treated and incubated with LPS (1 pg/ml, E. coli serotype 055:B5, Sigma-Aldrich) for 24 hours.
As a result, it could be seen that the expression of TNF-a, IL-113 and IL-6, which are activated and expressed by LPS, was inhibited by the nt-p65-TMD
recombinant fusion protein (see FIG. 7).
4-3: Confirmation of Specific Inhibitory Effect against NF-03 Transcription Factor in Jurkat T Cells Whether or not the nt-p65-TMD recombinant fusion protein of Example 1 specifically inhibits the transcription of NF-x13 activated by Jurkat T-cell activation stimulated by anti-CD3 (1 jig/ml, BD Pharmingen) and anti-CD28 (1 jig/ml, BD
Pharmingen) was examined. When T cells are activated, not only NF-KB
transcription but also NFAT transcription is activated. For this reason, if the nt-p65-TMD
fusion protein inhibits only NF-KB transcription without influencing NFAT
transcription, it can be seen that the nt-p65-TMD recombinant fusion protein acts as a specific competitive inhibitor of NF-x13. To confirm this fact, luciferase reporter gene was used.
First, NF-K13 and NFAT reporter genes having luciferase in the downstream region were transfected into the nucleus of Jurkat T cells by elctroporation, and then the Jurkat T cells were stimulated with anti-CD3 and anti-CD28 and treated with the nt-p65-TMD
recombinant fusion protein.
As a result, it could be seen that, when the NF-03-transfected cells were treated with the recombinant fusion protein, the expression of luciferase in the cells was effectively inhibited, but NFAT was not influenced by the recombinant fusion protein (see FIG. 8a).
4-4: Phosphorylation of Intracellular Signal Transduction Protein In order to examine whether or not the nt-p65-TMD recombinant fusion protein of Example 1 is involved in tyrosine phosphorylation of proteins related to various intracellular signal transduction systems, Western blot analysis was performed. Jurkat T cells were treated with 2 [IM of nt-p65-TMD for 1 hour, and then stimulated with anti-CD3 (2.5 jig/ml) and anti-CD28 (2.5 gimp, and whether or not tyrosine phosphorylation of ZAP-70, p38, JNK or ERK occurred was observed.
As a result, it could be seen that nt-p65-TMD did not influence phosphorylation of these proteins (see FIG. 8b).
4-5: Inhibition of Production of Cytokines (IL-2, IFN-y, IL-4, IL-17A and IL-10) in Splenocytes Splenocytes isolated from the spleens of 6-8-week-old female C57BL/6 mice were treated with the nt-p65-TMD recombinant fusion protein of Example I for 1 hour to transduce the recombinant fusion protein into the cells. The cells were stimulated with anti-CD3 (1 14/m1) and anti-CD28 (1 gimp, and then incubated for 72 hours.
Next, the amounts of cytokines present in the medium were measured by ELISA.
As a result, it could be seen that, when the cells were treated with nt-p65-TMD, the expression levels of 1L-2, IFN-y, IL-4, IL-17A and IL-10 in the cells were greatly inhibited. In addition, the expression level of CD69, which is indicative of T
cell activation, was measured by FACS Calibur (BD Biosciences), and as a result, it could be seen that nt-p65-TMD did not influence the expression of CD69 in T cells (FIG.
9).
Example 5: Evaluation of Therapeutic Effect of nt-p65-TMD in Septic Shock Animal Models LPS (20 mg/kg) was injected intraperitoneally into 6-8-week-old male BALB/c mice to make septic shock animal models. After 2 hours and 14 hours, the nt-p65-TMD
recombinant fusion protein of Example I was injected intraperitoneally into the animal models, followed by observation for 6 days.
As a result, it could be seen that, when the animal models were treated with nt-p65-TMD, the secretion of inflammatory cytokines (TNF-a, IL-1I3 and IL-6) was inhibited to thereby greatly increase the survival rate of the animal models (see FIG. 10).
Example 6: Acute Toxicity Test for Recombinant Fusion Protein Using 6-week-old specific pathogen-free (SPF) rats obtained from the Daehan Experiment Supply Center, an acute toxicity test was performed in the following manner.
The recombinant fusion protein of Example I was administered orally once to each animal group (consisting of two animals) at a dose of 1 g/kg, and then the death, clinical symptoms and weight changes of the animals were observed, and hematological tests and blood biochemical tests were performed. In addition, the animals were autopsied, and whether or not the abdominal organs and the thoracic organs were abnormal was visually observed.
As a result, in all the animals administered with the test substance, specific clinical symptoms or dead animals were not found, and in the weight change measurement, hematological tests, blood biochemical tests and autopsy findings, no change in toxicity was observed. Thus, it could be seen that the recombinant fusion protein of the present invention showed no toxicity in the rats even at a dose of I g/kg and that the minimum lethal dose (LD50) upon oral administration thereof was I
g/kg or more, suggesting that it is a safe substance.
References Park et al., Intranuclear interactomic inhibition of NF-kB suppresses LPS-induced severe sepsis, Biochemical and Biophysical Research Communications, 2015;
464:711-717.
Although the present disclosure has been described in detail with reference to the specific features, it will be apparent to those skilled in the art that this description is only of a preferred embodiment thereof, and does not limit the scope of the present invention. Thus, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof.
FIG. 10 shows results indicating that the fusion protein (nt-p65-TMD) of the present invention inhibits the secretion of inflammatory cytokines (TNF-a, IL-113 and IL-6) in septic shock animal models to thereby increase the survival rate of the animal models.
(Best Mode]
Hereinafter, the present invention will be described in further detail with reference to examples. It will be obvious to those skilled in the art that these examples are for illustrative purposes and are not intended to limit the scope of the present invention.
Examples Example 1: Preparation of a Recombinant Fusion Protein Comprising p65 Transcription Modulation Domain and Protein Transduction Domain The protein transduction domain (PTD) Hph-1 (SEQ ID NO: 4) was cloned into the p65 transcription modulation domain p65-TMD (SEQ ID NO: 2) and a pET-28a(+) vector (Novagen) to thereby construct a recombinant fusion DNA (nt-p65-TMD) (SEQ
ID NO: 6). The recombinant fusion DNA was transformed into a BL21 CodonPlus(DE3)-RIPL E. coli strain (Invitrogen). The transformed strain was cultured, and then treated with 1 mM IPTG (isopropy143-D-thiogalactopyranoside, Duchefa), after which protein expression in the strain was induced at 37 C for 5 hours. Next, only the cells were harvested, lysed with lysis buffer (10 mM imidazole, 50 mM NaH2PO4, mM NaC1, pH 8.0), and then disrupted with a homogenizer. The fusion protein was bound to Ni-NTA beads (Qiagen) by 6 histidine residues linked to the upstream region of the protein. The protein was loaded onto HisTrap chromatography columns (Bio-Rad), and washed sufficiently with washing buffer (30 mM imidazole, 50 mM NaH2PO4, mM NaC1, pH 8.0), and the protein was eluted with elution buffer (250 mM
imidazole, 50 mM NaH2PO4, 300 mM NaC1 and pH 8.0). Using PD-10 Sephadex G-25 (GE
Healthcare), imidazole and NaC1 were removed while the buffer was replaced with 10%
glycerol-containing PBS. Because the obtained protein contained endotoxins such as LPS, it was purified once more using SP beads (SP Sepharose 1m Fast Flow, GE
Healthcare) to remove the endotoxins. The resulting protein was bound using binding buffer (50 mM NaH2PO4, 300 mM NaC1, pH 6.0), and then loaded onto a column and eluted with elution buffer (50 mM NaH2PO4, 2 M NaC1, pH 6.0). Finally, NaCI
was removed using PD-10 Sephadex G-25, and the buffer was placed with 10% glycerol-containing PBS, after which the resulting protein (SEQ ID NO: 5, recombinant fusion protein) was stored at 80 C until use in experiments (see FIGS. 1 and 2).
Example 2: Analysis of Intracellular Transduction of nt-p65-TMD
Recombinant Fusion Protein 2-1: Analysis of Intracellular Transduction by Western Blotting BV2 microglial cells and Jurkat T cells were incubated with the recombinant fusion protein (nt-p65-TMD) at varying protein concentrations (0, 0.1, 0.5, 1, 2 and 5 [tM) or for varying times (0, 1, 2, 4, 6, 12, 24 and 48 hours), and whether or not the fusion protein was transduced was analyzed by Western blotting.
As a result, it was shown that the fusion protein was well transduced in proportion to the concentration thereof and was continuously transduced even at 48 hours while the protein in the cell culture maintained its structure (see FIG. 3).
2-2: Analysis of Whether or Not Fusion Protein is Transduced to Nucleus of Cells, by Use of Antibody 5 ptM of the recombinant fusion protein (nt-p65-TMD) of Example 1 was incubated with BV2 microglial cells and HeLa cells for 1 hour and washed with PBS, after which the cells were treated with 0.2% Triton X-100 (Sigma-Aldrich) to form an opening, and a fluorescence-labeled antibody was bound to the recombinant fusion protein through the opening. Next, the nucleus of the cells was stained with DAPI dye (Invitrogen), and then the location of fluorescence was determined by a fluorescence microscope to thereby determine the location to which the recombinant fusion protein was transduced.
As a result, it was shown that the fusion protein was well transduced to the nucleus of the cells by the property of the PTD (see FIG. 4).
Example 3: Analysis of Cytotoxicity of nt-p65-TMD Recombinant Fusion Protein In order to confirm that the protein obtained from the E. coli strain by expression is completely free of LPS so that it is not toxic to cells or animals, a cytotoxicity test was performed. Varying concentrations of the protein were transduced into BV2 microglial cells and splenocytes, and then the cells were incubated with WST-8, a substrate that develops color by dehydrogenase present in living cells.
As a result, it could be seen that the cells treated with the fusion protein showed no cytotoxicity regardless of the concentration of the fusion protein, unlike cells not treated with the protein (FIG. 5).
Example 4: Confirmation of the Effect of nt-p65-TMD Recombinant Fusion Protein on Specific Inhibition of Transcription Factor 4-1: Confirmation of Inhibitory Effect against Transcription of NF-KB and IL-2 in HEI(293T Cells To directly confirm whether or not the nt-p65-TMD recombinant fusion protein of Example 1 binds to the promoters of the NF-03 and 1L-2 cytokine genes in place of wild-type p65 to inhibit the expression of the genes, luciferase reporter gene was used.
First, each of NF-KB and IL-2 promoters and wild-type p65 gene, which have luciferase in the downstream region, was transfected into the nucleus of HEK293T cells, and then the cells were treated with the nt-p65-TMD recombinant fusion protein.
As a result, it could be seen that, when the cells were treated with the recombinant fusion protein, the expression of luciferase in the cells was effectively inhibited. This suggests that nt-p65-TMD acted as a competitive inhibitor of wild-type p65 to block the p65-binding site of each of the NF-KB and IL-2 promoters (see FIG. 6).
4-2: Confirmation of Inhibitory Effect against Secretion of Inflammatory Cytokines in BV2 Microglial Cells BV2 microglial cells were treated with the nt-p65-TMD recombinant fusion protein of Example 1, and after 1 hour, the cells were treated and incubated with LPS (1 pg/ml, E. coli serotype 055:B5, Sigma-Aldrich) for 24 hours.
As a result, it could be seen that the expression of TNF-a, IL-113 and IL-6, which are activated and expressed by LPS, was inhibited by the nt-p65-TMD
recombinant fusion protein (see FIG. 7).
4-3: Confirmation of Specific Inhibitory Effect against NF-03 Transcription Factor in Jurkat T Cells Whether or not the nt-p65-TMD recombinant fusion protein of Example 1 specifically inhibits the transcription of NF-x13 activated by Jurkat T-cell activation stimulated by anti-CD3 (1 jig/ml, BD Pharmingen) and anti-CD28 (1 jig/ml, BD
Pharmingen) was examined. When T cells are activated, not only NF-KB
transcription but also NFAT transcription is activated. For this reason, if the nt-p65-TMD
fusion protein inhibits only NF-KB transcription without influencing NFAT
transcription, it can be seen that the nt-p65-TMD recombinant fusion protein acts as a specific competitive inhibitor of NF-x13. To confirm this fact, luciferase reporter gene was used.
First, NF-K13 and NFAT reporter genes having luciferase in the downstream region were transfected into the nucleus of Jurkat T cells by elctroporation, and then the Jurkat T cells were stimulated with anti-CD3 and anti-CD28 and treated with the nt-p65-TMD
recombinant fusion protein.
As a result, it could be seen that, when the NF-03-transfected cells were treated with the recombinant fusion protein, the expression of luciferase in the cells was effectively inhibited, but NFAT was not influenced by the recombinant fusion protein (see FIG. 8a).
4-4: Phosphorylation of Intracellular Signal Transduction Protein In order to examine whether or not the nt-p65-TMD recombinant fusion protein of Example 1 is involved in tyrosine phosphorylation of proteins related to various intracellular signal transduction systems, Western blot analysis was performed. Jurkat T cells were treated with 2 [IM of nt-p65-TMD for 1 hour, and then stimulated with anti-CD3 (2.5 jig/ml) and anti-CD28 (2.5 gimp, and whether or not tyrosine phosphorylation of ZAP-70, p38, JNK or ERK occurred was observed.
As a result, it could be seen that nt-p65-TMD did not influence phosphorylation of these proteins (see FIG. 8b).
4-5: Inhibition of Production of Cytokines (IL-2, IFN-y, IL-4, IL-17A and IL-10) in Splenocytes Splenocytes isolated from the spleens of 6-8-week-old female C57BL/6 mice were treated with the nt-p65-TMD recombinant fusion protein of Example I for 1 hour to transduce the recombinant fusion protein into the cells. The cells were stimulated with anti-CD3 (1 14/m1) and anti-CD28 (1 gimp, and then incubated for 72 hours.
Next, the amounts of cytokines present in the medium were measured by ELISA.
As a result, it could be seen that, when the cells were treated with nt-p65-TMD, the expression levels of 1L-2, IFN-y, IL-4, IL-17A and IL-10 in the cells were greatly inhibited. In addition, the expression level of CD69, which is indicative of T
cell activation, was measured by FACS Calibur (BD Biosciences), and as a result, it could be seen that nt-p65-TMD did not influence the expression of CD69 in T cells (FIG.
9).
Example 5: Evaluation of Therapeutic Effect of nt-p65-TMD in Septic Shock Animal Models LPS (20 mg/kg) was injected intraperitoneally into 6-8-week-old male BALB/c mice to make septic shock animal models. After 2 hours and 14 hours, the nt-p65-TMD
recombinant fusion protein of Example I was injected intraperitoneally into the animal models, followed by observation for 6 days.
As a result, it could be seen that, when the animal models were treated with nt-p65-TMD, the secretion of inflammatory cytokines (TNF-a, IL-1I3 and IL-6) was inhibited to thereby greatly increase the survival rate of the animal models (see FIG. 10).
Example 6: Acute Toxicity Test for Recombinant Fusion Protein Using 6-week-old specific pathogen-free (SPF) rats obtained from the Daehan Experiment Supply Center, an acute toxicity test was performed in the following manner.
The recombinant fusion protein of Example I was administered orally once to each animal group (consisting of two animals) at a dose of 1 g/kg, and then the death, clinical symptoms and weight changes of the animals were observed, and hematological tests and blood biochemical tests were performed. In addition, the animals were autopsied, and whether or not the abdominal organs and the thoracic organs were abnormal was visually observed.
As a result, in all the animals administered with the test substance, specific clinical symptoms or dead animals were not found, and in the weight change measurement, hematological tests, blood biochemical tests and autopsy findings, no change in toxicity was observed. Thus, it could be seen that the recombinant fusion protein of the present invention showed no toxicity in the rats even at a dose of I g/kg and that the minimum lethal dose (LD50) upon oral administration thereof was I
g/kg or more, suggesting that it is a safe substance.
References Park et al., Intranuclear interactomic inhibition of NF-kB suppresses LPS-induced severe sepsis, Biochemical and Biophysical Research Communications, 2015;
464:711-717.
Although the present disclosure has been described in detail with reference to the specific features, it will be apparent to those skilled in the art that this description is only of a preferred embodiment thereof, and does not limit the scope of the present invention. Thus, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof.
Claims (17)
1. A fusion protein comprising a transcription modulation domain of NF-.kappa.B and a protein transduction domain, wherein the fusion protein inhibits NF-.kappa.B
transcription by competitive inhibition.
transcription by competitive inhibition.
2. The fusion protein of claim 1, wherein the NF-.kappa.B is NF-.kappa.B
selected from the group consisting of RelA (p65), c-Rel, Rel-B, NF-.kappa.B1 (p50) and NF-.kappa.B2 (p52).
selected from the group consisting of RelA (p65), c-Rel, Rel-B, NF-.kappa.B1 (p50) and NF-.kappa.B2 (p52).
3. The fusion protein of claim 1, wherein the NF-.kappa.B is RelA (p65).
4. The fusion protein of claim 1, wherein the transcription modulation domain of NF-.kappa.B comprises an amino acid sequence of SEQ ID NO: 1.
5. The fusion protein of claim 4, wherein the transcription modulation domain of NF-.kappa.B is encoded by a nucleotide sequence of SEQ ID NO: 3.
6. The fusion protein of claim 1, wherein the protein transduction domain is selected from the group consisting of Hph-1, Sim-2, Tat, VP22, Antp (antennapedia), Pep-1 (peptide-1), PTD-5 (protein transduction domain-5), 7R, 9R, 11R and CTP
(cytoplasmic transduction peptide).
(cytoplasmic transduction peptide).
7. The fusion protein of claim 1, wherein the protein transduction domain is Hph-1.
8. The fusion protein of claim 1, wherein the protein transduction domain comprises an amino acid sequence of SEQ ID NO: 2.
9. The fusion protein of claim 8, wherein the protein transduction domain is encoded by a nucleotide sequence of SEQ ID NO: 4.
10. The fusion protein of claim 1, wherein the fusion protein comprises an amino acid sequence of SEQ ID NO: 5.
11. The fusion protein of claim 10, wherein the fusion protein is encoded by a nucleotide sequence of SEQ ID NO: 6.
12. An inhibitor of NF-.kappa.B transcription or activity, comprising the fusion protein of claim 1.
13. A pharmaceutical composition for prevention or treatment of a disease related to NF-.kappa.B overactivity, the composition comprising the fusion protein of claim 1 as an active ingredient.
14. The composition of claim 13, wherein the disease related to NF-.kappa.B
overactivity is an inflammatory disease or an autoimmune disease.
overactivity is an inflammatory disease or an autoimmune disease.
15. The composition of claim 13, wherein the disease related to NF-.kappa.B
overactivity is a disease selected from the group consisting of septic shock, allergic asthma, allergic nasitis, atopic dermatitis, systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, dacryoadenitis, Alzheimer's disease, stroke, arteriosclerosis, vascular restenosis, type I diabetes, type II diabetes, urticaria, conjunctivitis, psoriasis, systemic inflammatory response syndrome, polymyositis, dermatomyositis, polyarthritis nodosa, mixed connective tissue disease, Sjogren's syndrome, gout, Parkinson's disease, amyotrophic lateral sclerosis, diabetic retinopathy, multiple sclerosis, Crohn's disease, chronic thyroiditis, Celiac disease, myasthenia gravis, pemphigus vulgaris, viral diseases, bacterial diseases, radiation-induced disorders, arteriosclerosis, hemangioma, angiofibroma, reperfusion injury, and cardiac hypertrophy.
overactivity is a disease selected from the group consisting of septic shock, allergic asthma, allergic nasitis, atopic dermatitis, systemic lupus erythematosus, rheumatoid arthritis, ulcerative colitis, dacryoadenitis, Alzheimer's disease, stroke, arteriosclerosis, vascular restenosis, type I diabetes, type II diabetes, urticaria, conjunctivitis, psoriasis, systemic inflammatory response syndrome, polymyositis, dermatomyositis, polyarthritis nodosa, mixed connective tissue disease, Sjogren's syndrome, gout, Parkinson's disease, amyotrophic lateral sclerosis, diabetic retinopathy, multiple sclerosis, Crohn's disease, chronic thyroiditis, Celiac disease, myasthenia gravis, pemphigus vulgaris, viral diseases, bacterial diseases, radiation-induced disorders, arteriosclerosis, hemangioma, angiofibroma, reperfusion injury, and cardiac hypertrophy.
16. A method for inhibiting transcription or activity of NF-.kappa.B, the method comprising administering a composition comprising the fusion protein of claim 1 as an active ingredient.
17. A method of preventing, improving or treating a disease related to NF-.kappa.B
overactivity, the method comprising administering, to a subject in need, a composition comprising the fusion protein of claim 1 as an active ingredient.
overactivity, the method comprising administering, to a subject in need, a composition comprising the fusion protein of claim 1 as an active ingredient.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/KR2016/000104 WO2017119521A1 (en) | 2016-01-06 | 2016-01-06 | Novel fusion protein comprising transcription modulation domain of p65 and protein transport domain and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3010811A1 true CA3010811A1 (en) | 2017-07-13 |
Family
ID=59274225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3010811A Pending CA3010811A1 (en) | 2016-01-06 | 2016-01-06 | Novel fusion protein comprising transcription modulation domain of p65 and protein transport domain and use thereof |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP7051687B2 (en) |
| AU (1) | AU2016385177B2 (en) |
| CA (1) | CA3010811A1 (en) |
| WO (1) | WO2017119521A1 (en) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010509181A (en) * | 2005-11-04 | 2010-03-25 | フォーヒューマンテック・カンパニー・リミテッド | Methods for transporting fusion polypeptides into cells |
| KR101525856B1 (en) * | 2010-08-20 | 2015-06-04 | 연세대학교 산학협력단 | A inhibitor for transcription factor of fusion protein comprising DNA binding domain of transcription factor and protein transduction domain |
| EP3424946B1 (en) * | 2010-08-20 | 2021-08-04 | Good T Cells, Inc. | A fusion protein having transcription modulating domain and a protein transduction domain, and an inhibitor for transcription factor function comprising the same |
-
2016
- 2016-01-06 JP JP2018536197A patent/JP7051687B2/en active Active
- 2016-01-06 AU AU2016385177A patent/AU2016385177B2/en active Active
- 2016-01-06 WO PCT/KR2016/000104 patent/WO2017119521A1/en active Application Filing
- 2016-01-06 CA CA3010811A patent/CA3010811A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016385177A1 (en) | 2018-08-09 |
| JP7051687B2 (en) | 2022-04-11 |
| JP2019507117A (en) | 2019-03-14 |
| WO2017119521A1 (en) | 2017-07-13 |
| AU2016385177B2 (en) | 2023-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nan et al. | TNFR2 stimulation promotes mitochondrial fusion via Stat3-and NF-kB–dependent activation of OPA1 expression | |
| Angelini et al. | FtsY, the bacterial signal‐recognition particle receptor, interacts functionally and physically with the SecYEG translocon | |
| Bode et al. | The macrophage response towards LPS and its control through the p38MAPK–STAT3 axis | |
| TWI640320B (en) | Anti-inflammatory peptides and composition comprising the same（3） | |
| Pellegrini et al. | MTERF2 is a nucleoid component in mammalian mitochondria | |
| Du et al. | Suppression of NF-κB by cyclosporin A and tacrolimus (FK506) via induction of the C/EBP family: implication for unfolded protein response | |
| Praveen et al. | Constitutive expression of tumor necrosis factor-alpha in cytotoxic cells of teleosts and its role in regulation of cell-mediated cytotoxicity | |
| Jana et al. | Involvement of phosphatidylinositol 3-kinase-mediated up-regulation of IκBα in anti-inflammatory effect of gemfibrozil in microglia | |
| Feng et al. | Structure–affinity relationship analysis of selective FKBP51 ligands | |
| Field et al. | BNIP3 and Nix: Atypical regulators of cell fate | |
| Jiang et al. | Celastrol is a novel selective agonist of cannabinoid receptor 2 with anti-inflammatory and anti-fibrotic activity in a mouse model of systemic sclerosis | |
| Harama et al. | A subcytotoxic dose of subtilase cytotoxin prevents lipopolysaccharide-induced inflammatory responses, depending on its capacity to induce the unfolded protein response | |
| US11414467B2 (en) | Fusion protein comprising transcription modulation domain of p65 and protein transduction domain, and uses thereof | |
| Kino et al. | Human immunodeficiency virus type‐1 accessory protein Vpr: a causative agent of the AIDS‐related insulin resistance/lipodystrophy syndrome? | |
| Hwang et al. | NFAT1 and JunB cooperatively regulate IL-31 gene expression in CD4+ T cells in health and disease | |
| US20240041988A1 (en) | Use of elapidae postsynaptic neurotoxin in the treatment of over expression of inflammatory cytokines related diseases | |
| AU2016385177B2 (en) | Novel fusion protein comprising transcription modulation domain of P65 and protein transport domain and use thereof | |
| CN113999854B (en) | Application of polypeptide and carrier thereof in myocardial ischemia reperfusion injury | |
| US20240254189A1 (en) | Ultrahigh-affinity small protein targeting pd-l1 and use | |
| US20190315820A1 (en) | A Composition Containing SMAD Protein for Treatment of Autoimmune Diseases, a Fusion Protein Comprising SMAD Protein, an Expression Vector and a Method for Preparing the Same | |
| Miaw et al. | A repressor of GATA-mediated negative feedback mechanism of T cell activation | |
| Ouyang et al. | Potential mechanistic roles of Interleukin-33 in rheumatoid arthritis | |
| Damough et al. | Optimization of culture conditions for high-level expression of soluble and active tumor necrosis factor-α in E. coli | |
| Dunbar et al. | Two-hybrid cloning of a gene encoding TNF receptor-associated protein 2, a protein that interacts with the intracellular domain of the type 1 TNF receptor: identity with subunit 2 of the 26S protease. | |
| EP4046648A1 (en) | Application of elapidae snake postsynaptic neurotoxin monomer molecule in treatment of alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20201210 |
|
| EEER | Examination request |
Effective date: 20201210 |
|
| EEER | Examination request |
Effective date: 20201210 |
|
| EEER | Examination request |
Effective date: 20201210 |
|
| EEER | Examination request |
Effective date: 20201210 |
|
| EEER | Examination request |
Effective date: 20201210 |
|
| EEER | Examination request |
Effective date: 20201210 |
|
| EEER | Examination request |
Effective date: 20201210 |